Eisai prevails against Teva/Dr. Reddy's over Aciphex

YNET reported that the US District Court for the Southern District of New York upheld Eisai's patent on the drug, Aciphex, a decision adverse to Teva, who had already received Food and Drug Administration approval for the generic version.

Judge Gerard Lynch noted that "defendants have failed to establish their defense of inequitable conduct by clear and convincing evidence." [Dr. Reddy's Laboratories Ltd. of India was also involved in the case.]

Johnson & Johnson Inc. co-markets Aciphex with Eisai reported $1.24 billion in 2006 sales of the acid reflux drug worldwide.